Dr. Arifa S. Khan is Head of the Molecular Retrovirology Unit, Division of Viral Products, Office of Vaccines Research and Review, in the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. She moved her retrovirus research program from NIAD/NIH to CBER in 1991, where she is currently leading efforts for applications of high-throughput sequencing for endogenous retrovirus and adventitious virus detection for the safety evaluation of biologics. Her primary regulatory responsibilities include viral vaccines, including those for HIV-1, influenza virus, and SARS-COV-2. She also provides expert consultation on viral safety and testing to OTAT/CBER and CDER. She has been involved in the licensure of several viral vaccines and the development of FDA, ICH, PHS, USP, and WHO documents. She obtained her Ph.D. in Microbiology from George Washington University, Washington, DC, USA. She has authored more than 100 publications.